q3 earnings per share $1.15 from continuing operations.
qtrly adjusted ebitda of $130 million, up 70% from 2019 levels.
expects capital expenditures for 2021 to be approximately $110 million, excluding impact of alg.
revpar in q3 continued to recover at a robust pace, accelerating nearly 30% compared to q2.
reaffirming its expectation for room growth to be greater than 6% for full year.
q3 adjusted ebitda $110 million.
for full year of 2021, adjusted sg&a is expected to be in range of $5 million to $10 million.
qtrly total cash of $2.7 billion for acquisition of alg.